Eli Lilly (LLY)

High hopes for a freshly approved drug might not be realized, if early data is any indication.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription number...

Major M&A deals this week include Eli Lilly buys Kelonia for $7 billion, Honeywell sells PSS to Brady Corp., KSL buys Invited Clubs.

Eli Lilly stock skidded early Friday as Novo Nordisk's oral Wegovy continued to outpace Lilly's new obesity pill, Foundayo.

Young adults with median earnings can build sizable portfolios by retirement by regularly purchasing shares of the Vanguard S&P 500 Growth ETF.

Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking...

Federated Hermes delivers asset management solutions across equity, fixed income, and money market funds to a diverse client base.

Amazon is expanding into integrated weight-loss care with a scalable healthcare model. Can this expansion meaningfully drive AMZN stock upside?

Novo Nordisk stock has been stuck in a downward spiral for quite some time.

Hims & Hers Health can now connect its customers with self-pay prices for Eli Lilly's weight-loss drugs.

Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

These companies offer a clear path to sustained earnings growth.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...

Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance.

What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...

Can Eli Lilly cure cancer? Maybe -- with a little help.

Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics fell Tuesday after Amazon announced it would sell weight-loss drugs.

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Two analysts weighed in positively about the company's future.

Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.

Eli Lilly's nuclear move signals a shift beyond AI, as industrial giants like Nucor and Dow turn to reactors for reliable, 24/7 power.